A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Contributors

Brander, Danielle Marie Principal Investigator

Start/End

October 1, 2015 - September 30, 2022